Gelonghui November 15th 丨 Investor Relations Activity Record of Shenzhou Cell (688520.SH) shows that SCT-I10A monoclonal antibody has two indications for liver cancer and head and neck cancer in the market approval stage, with no other indications currently planned for market approval.
神州细胞(688520.SH)：SCT-I10A单抗已有肝癌和头颈癌两个适应症正在上市审评阶段
Shenzhou Cell (688520.SH): The SCT-I10A monoclonal antibody has two indications for liver cancer and head and neck cancer in the market approval stage.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated